Role of Tigecycline in Pneumonia Treatment
Introduction to Tigecycline Use
- Tigecycline should not be used as monotherapy for the treatment of pneumonia, particularly hospital-acquired or ventilator-associated pneumonia, due to higher mortality rates and treatment failure compared to alternative therapies 1, 2
Evidence Against Monotherapy
- Tigecycline monotherapy has demonstrated a higher rate of treatment failure compared to colistin monotherapy, colistin combination therapy, and sulbactam-based therapy for carbapenem-resistant Acinetobacter baumannii (CRAB) pneumonia 1, 3
- A matched cohort study comparing colistin versus tigecycline favored colistin-based therapy for multi-drug-resistant (MDR) pneumonia 1
- The excess mortality with tigecycline may be related to higher A. baumannii MIC of tigecycline (>2 mg/mL) 1
- Guidelines strongly recommend against tigecycline monotherapy for the treatment of CRAB pneumonia 4
Combination Therapy Considerations
- For carbapenem-resistant Acinetobacter baumannii (CRAB) pneumonia, tigecycline may be considered as part of combination therapy when the MIC is ≤2 mg/L 5
- A randomized study of extensively drug-resistant A. baumannii ventilator-associated pneumonia showed that combination of tigecycline and cefoperazone-sulbactam had synergistic activity and higher clinical response rates than tigecycline monotherapy 1
- For CRAB pneumonia, guidelines suggest colistin with or without carbapenems as the preferred treatment, with tigecycline only as part of combination therapy in specific scenarios 4, 5
Alternative Treatments
- For CRAB pneumonia, colistin (with or without carbapenems) and adjunctive inhaled colistin therapy is recommended as first-line treatment 4, 5
- Alternative treatments for CRAB pneumonia include high-dose sulbactam (6-9 g/day) or triple therapy with colistin, tigecycline, and sulbactam 5
- For Pseudomonas aeruginosa infections, tigecycline is not recommended due to inadequate activity 7
Pharmacokinetic and Adverse Effect Considerations
- Despite good tissue penetration, tigecycline performs poorly in bacteremic patients due to low plasma concentrations 6
- The clinical efficacy of tigecycline is associated with its MIC value against MDR organisms - comparable to polymyxin when MIC ≤2 mg/L, but inferior when MIC >2 mg/L 6
- Common adverse effects include nausea, vomiting, and diarrhea 6
- Patients should be monitored for adverse effects, particularly gastrointestinal symptoms and liver function abnormalities 6